Evaluation of the clinical safety and efficacy of iobitridol (Xenetix) in intravenous urography.
The aim of this study is to report on the clinical safety and diagnostic efficacy of iobitridol (Xenetix) in intravenous urography compared to iohexol (Omnipaque) or iopamidol (Iopamiro). A total of 120 patients underwent intravenous urography (i.v.u.); 60 received Xenetix and 60 either Omnipaque (30 patients) or Iopamiro (30 patients) according to the center where they were treated. Clinical safety was assessed by the reporting of adverse events and diagnostic efficacy was evaluated. Warmth sensation was the most commonly reported adverse event. Two cases of nausea and vomiting were reported. Concerning diagnostic efficacy, 72-74% of the i.v.u. examinations were rated good or excellent by the physician. These studies confirm that Xenetix is a suitable contrast agent for i.v.u.
Fournier
P J
PJ
Department of Radiology, University Hospital, Basle, Switzerland.
Steinbrich
W
W
Freitag
P
P
Voegeli
E
E
D003287:Contrast Media / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007472:Iohexol / Q000009:adverse effects / Q000031:analogs & derivatives*; D007479:Iopamidol / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D012449:Safety; D014567:Urography / Q000379:methods*
D003287:Contrast Media; C093233:iobitridol; D007472:Iohexol; D007479:Iopamidol